Anand Shridharani, MD
Urology · Chattanooga, TNNPI 1992834923
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.0%), education and food and beverage — rather than concentrated in one kind of arrangement. Coloplast accounts for 92.5% of it on its own, with 28 other manufacturers making up the rest. Among urology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $416.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$123K
- Boston Scientific$5K
- Teleflex LLC$1K
- Cook Medical LLC$460
- Endo Pharmaceuticals Inc.$358
- Procept Biorobotics Corporation$297
- plus $3K from 23 others
What the payments were for
- Consulting fees$64,03148%
- Travel & lodging$12,66910%
- Food & beverage$14,78411%
- Education$41,85531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 169 | $123,323 |
| Boston Scientific | 58 | $5,016 |
| Teleflex LLC | 20 | $1,165 |
| Cook Medical LLC | 4 | $460 |
| Endo Pharmaceuticals Inc. | 10 | $358 |
| Procept Biorobotics Corporation | 3 | $297 |
| Neotract Inc. | 4 | $254 |
| C. R. Bard, Inc. & Subsidiaries | 13 | $250 |
| Dornier Medtech America, Inc | 1 | $188 |
| Tolmar, Inc. | 2 | $183 |
| Palette Life Sciences, Inc. | 4 | $181 |
| Axonics, Inc. | 4 | $166 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $165 |
| Photocure Inc | 1 | $156 |
| Novo Nordisk | 2 | $155 |
| AstraZeneca | 1 | $126 |
| Urogen Pharma, Inc. | 1 | $125 |
| Antares Pharma, Inc. | 4 | $125 |
| Covidien LP | 1 | $118 |
| Sumitomo Pharma America, Inc. | 1 | $107 |
| Calyxo, Inc. | 1 | $88 |
| Endo USA, Inc. | 3 | $76 |
| KARL Storz Endoscopy-america | 1 | $69 |
| Laborie Medical Technologies Corp. | 5 | $62 |
| Ambu Inc. | 2 | $36 |
| Profound Medical Corp. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $22 |
| BD | 1 | $22 |
| Olympus America Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$78,265
- VIRTUE$32,601
- ALTIS$8,012
- Biatain Ag Non-Adhesive$1,800
- UroLift$521
- UroLift System$265
- LithoVue$265
- AquaBeam Robotic System$263
- AMS 700$250
- XIAFLEX$249
- Cook$223
- Dornier MedTech$188
- LITHO 150$188
- Cysview$156
- GENERAL MALE SUI$148
- rezum Generator$137
- GENERAL ERECTILE DYSFUNCTION$130
- JELMYTO$125
- REZUM$121
- GENERAL FEMALE SUI$121
How this compares
$133,339 in reported general payments places this provider in the 95th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 40 | $38,323 |
| MyrbetriqMirabegron | 47 | $27,949 |
| Solifenacin Succinate | 13 | $3,633 |
| Cabergoline | 30 | $1,970 |
| Tamsulosin Hcl | 107 | $1,067 |
| Testosterone Cypionate | 14 | $683 |
| Oxybutynin Chloride | 42 | $367 |
| Ciprofloxacin Hcl | 97 | $258 |
| Finasteride | 14 | $240 |
| Anastrozole | 29 | $181 |
| Meloxicam | 44 | $117 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 47 | $105 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $46 |
| Fluconazole | 12 | $27 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $107 | $38,32340 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $27,94947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 urology providers in Tennessee.
Other urology in Chattanooga
- Amar SinghChattanooga$57K
- Argil WheelockChattanooga$47K
- Jeffrey MullinsChattanooga$18K
- Benjamin WaldorfChattanooga$16K
- L KnollNashville$2.1M
- David GubinMemphis$1M
- Gautam JayramNashville$1M
- David MorrisHendersonville$871K
- Roger DmochowskiNashville$763K
- Paul EberGermantown$476K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.